Glucotrack (NASDAQ: GCTK) trims 2025 loss and readies IDE for implantable CBGM trials
Rhea-AI Filing Summary
Glucotrack, Inc. reported its fourth quarter and full year 2025 results and highlighted progress on its implantable continuous blood glucose monitoring (CBGM) technology. The company plans to file an Investigational Device Exemption (IDE) with the FDA in the second quarter of 2026, targeting a U.S. clinical trial launch in the second half of 2026, subject to IDE approval.
In December 2025, Glucotrack raised approximately $4.0 million in gross proceeds through the sale of 1,033,591 shares of common stock (or equivalents) and warrants to purchase up to 2,067,182 shares at a combined effective price of $3.87. For full year 2025, research and development expenses were $9.8 million versus $9.5 million in 2024, and general and administrative expenses were $6.3 million versus $5.1 million.
The 2025 net loss was $19.4 million, improving from a net loss of $22.6 million in 2024, largely due to prior-year non-cash losses. Cash and cash equivalents were $7.4 million at December 31, 2025, up from $5.6 million a year earlier. Management believes existing cash will fund its 2026 operating plan through spring, including the IDE submission and initiation of U.S. human clinical trials.
Positive
- None.
Negative
- None.
Insights
Glucotrack narrows losses, reinforces cash, and advances CBGM toward U.S. trials.
Glucotrack remains a development-stage company with no product revenue, but 2025 results show progress. Net loss decreased to $19.4M from $22.6M, mainly because prior-year non-cash losses did not recur, while operating expenses modestly increased as R&D and G&A grew.
Cash rose to $7.4M at December 31, 2025, helped by $17.0M from financing activities, including a December equity and warrant offering of about $4.0M gross proceeds. Management states this cash should support the 2026 operating plan through spring, covering the IDE submission and start of U.S. human clinical trials.
The strategy centers on the fully implantable CBGM system. Key upcoming steps include filing the IDE in Q2 2026 and launching a U.S. feasibility study in the second half of 2026, subject to FDA approval. Future disclosures on trial initiation, enrollment, and safety and accuracy data will be important for assessing development risk and timelines.
8-K Event Classification
Key Figures
Key Terms
Investigational Device Exemption (IDE) regulatory
continuous blood glucose monitoring (CBGM) medical
derivative financial liabilities financial
feasibility study medical
Promissory notes financial
operating lease right-of-use asset financial
Earnings Snapshot
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction | (Commission | (IRS Employer | ||
| of Incorporation) | File Number) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 30, 2026, Glucotrack, Inc. (the “Company”) issued a press release announcing its financial and operating results for the year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
The information in Item 2.02 of this Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release, dated March 30, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 30, 2026 | ||
| GLUCOTRACK, INC. | ||
| By: | /s/ Paul Goode | |
| Name: | Paul Goode | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
Glucotrack Reports Fourth Quarter and Full Year 2025
Financial Results and Recent Corporate Highlights
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026
US Patent and Trademark Office (USPTO) issued patents for Glucotrack’s implantable
continuous blood glucose monitoring (CBGM) technology, strengthening the Company’s
intellectual property portfolio
Rutherford, NJ, March 30, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2025.
“In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring technology and strengthening Glucotrack’s foundation. We strengthened our competitive position with three new patents issued by the USPTO and continued to work closely with the FDA on alignment as we progress toward securing IDE approval and initiating our U.S. clinical study program of our CBGM product,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “We entered 2026 with strong momentum and a reinforced balance sheet, positioning the Company to execute on important development and regulatory milestones.”
Fourth Quarter 2025 & Recent Highlights
Corporate Highlights
| ● | Completed $4.0 million private placement. |
| ○ | In December 2025, the Company entered into a securities purchase agreement with a single institutional investor for the sale of 1,033,591 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,067,182 shares of common stock at a combined effective price of $3.87 per share and accompanying warrant, resulting in aggregate gross proceeds of approximately $4.0 million before fees and expenses. | |
| ○ | The Company expects to use the net proceeds from the offering for working capital and general corporate purposes. |
| ● | Strengthened the Company’s intellectual property portfolio for novel implantable CBGM platform. The three patents protect key technologies in Glucotrack’s CBGM system, a long-term implantable device designed for three-year sensor longevity, including proprietary sensor chemistry, intravascular lead design, and low-power electronics. Together, these innovations bridge the gap between short-lived subcutaneous sensors and larger pacemaker-class devices. |
| ● | Appointed Usman Latif, MD, MBA, to the Company’s clinical advisory team. Dr. Latif is a prominent pain management specialist and opinion leader with deep expertise in neuromodulation and treatment of painful diabetic neuropathy (PDN). This expertise will be invaluable as the Company advances its epidural glucose monitoring applications and integrates disease and device management solutions for PDN patients. | |
| ● | The Company held its second Patient Advisory Board (PAB) meeting during which patients provided feedback on the mobile application Glucotrack is developing to accompany its CBGM technology. |
Advanced Product and Clinical Development
| ● | The Company initiated a long-term, multicenter feasibility study in Australia to evaluate the CBGM product performance and safety. The first phase of the clinical study provided early product learnings about how the complexity of certain health conditions may impact study eligibility as well as identified certain product improvements. Consequently, the Company is expediting discussions with the U.S. Food and Drug Administration (FDA) regarding our planned U.S. clinical trial program that we expect to launch in the 2nd half of 2026, subject to FDA approval of our Investigational Device Exemption (“IDE”) submission expected to be filed in Second Quarter 2026. | |
| ● | Presented at the 2025 Diabetes Technology Meeting held on October 28th, 2025 on the importance of an integrated approach to diabetes management and highlighting how combining continuous glucose monitoring with existing implantable technologies can enable one implant to address multiple chronic conditions—redefining care for patients managing both diabetes and other chronic conditions. The presentation showcased the company’s preclinical work in epidural glucose monitoring which, when combined with spinal cord stimulation technologies, has the potential to offer integrated device and disease management for patients living with PDN. |
Anticipated Milestones
| ● | Submitting the Company’s IDE to the FDA in Second Quarter 2026 to initiate an initial human clinical Feasibility Study of the CBGM product, subject to current agency response timelines. | |
| ● | Presenting clinical data demonstrating the safety and accuracy of the CBGM product at additional industry conferences. | |
| ● | Further expanding Advisory Boards with world-renowned experts in endocrinology and cardiology and others essential to the diabetes community. | |
| ● | Continuing to gain insight from patients living with diabetes on current management challenges and get feedback on Glucotrack’s product development and commercialization strategies through additional PAB meetings. |
Financial Results for the Year Ended December 31, 2025
Research and Development Expenses: Research and development expenses were $9.8 million for the full year 2025 compared to $9.5 million for the full year 2024. The increase of $0.3 million was primarily attributable to increased activities related to product design, development and manufacturing activities and pre-clinical animal studies.
General and Administrative Expenses: General and administrative expenses were $6.3 million for the full year 2025 compared to $5.1 million for the full year 2024. The increase of $1.2 million was primarily attributable to increased professional fees, personnel costs and placement agent fees.
Net Loss: Net loss for the full year 2025 was $19.4 million compared to a net loss of $22.6 million for the full year 2024. The decrease of $3.2 million was primarily attributable to non-cash losses of $7.5 million related to the settlement of debt and the issuance of warrants containing derivative features recognized in the prior year.
Cash Position: Cash and cash equivalents as of December 31, 2025, were $7.4 million, compared with $5.6 million in cash and cash equivalents as of December 31, 2024. The net increase of $1.8 million in cash and cash equivalents compared to December 31, 2024 was attributable to the $17.0 million from financing activities offset by cash used in operating and investing activities of $15.3 million.
Based on current plans and assumptions, the Company believes that its existing cash and cash equivalents will be sufficient to fund its 2026 operating plan by the end of Spring allowing for its IDE submission and initiate U.S. human clinical trials in 2026.
# # #
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.
Contacts:
| Investor Relations: | Media: |
| investors@glucotrack.com | GlucotrackPR@icrinc.com |
GLUCOTRACK INC.
CONSOLIDATED BALANCE SHEETS
| In
thousands of US dollars (except stock data) | ||||||||
| December
31, 2025 | December
31, 2024 | |||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 7,383 | $ | 5,617 | ||||
| Other current assets | 284 | 151 | ||||||
| Total current assets | 7,667 | 5,768 | ||||||
| Operating lease right-of-use asset, net | 33 | 59 | ||||||
| Property and equipment, net | 138 | 95 | ||||||
| Restricted cash | - | 10 | ||||||
| TOTAL ASSETS | $ | 7,838 | $ | 5,932 | ||||
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | 1,317 | $ | 992 | ||||
| Operating lease liability, current | 28 | 26 | ||||||
| Promissory notes | 3,182 | - | ||||||
| Convertible promissory notes | - | 5 | ||||||
| Other current liabilities | 246 | 252 | ||||||
| Total current liabilities | 4,773 | 1,275 | ||||||
| Non-Current Liabilities | ||||||||
| Derivative financial liabilities | 1 | 17,421 | ||||||
| Operating lease liability, non-current | 5 | 33 | ||||||
| Loans from stockholders | 231 | 203 | ||||||
| Total liabilities | 5,010 | 18,932 | ||||||
| Commitments and contingent liabilities | ||||||||
| Stockholders’ (Deficit) Equity | ||||||||
| Common Stock of $0.001 par value (“Common Stock”): | ||||||||
| 250,000,000 shares authorized as of December 31, 2025 and 100,000,000 shares authorized as of December 31, 2024; 910,688 and 13,409 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1 | 1 | ||||||
| Additional paid-in capital | 151,080 | 119,229 | ||||||
| Receipts on account of shares | 3,544 | 228 | ||||||
| Accumulated other comprehensive income | 41 | (8 | ) | |||||
| Accumulated deficit | (151,838 | ) | (132,450 | ) | ||||
| Total stockholders’ (deficit) equity | 2,828 | (13,000 | ) | |||||
| TOTAL
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | $ | 7,838 | $ | 5,932 | ||||
GLUCOTRACK INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| In
thousands of US dollars (except stock and per stock amounts) | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses: | ||||||||
| Research and development expenses | $ | 9,813 | $ | 9,499 | ||||
| General and administrative expenses | 6,277 | 5,048 | ||||||
| Total operating expenses | 16,090 | 14,547 | ||||||
| Loss from operations | 16,090 | 14,547 | ||||||
| Other income (expense): | ||||||||
| Other (income) expense | (26 | ) | (14 | ) | ||||
| Change in fair value of derivative liability | 3,267 | 798 | ||||||
| Loss on equity issuance | - | 1,925 | ||||||
| Loss on settlement of liabilities | - | 4,758 | ||||||
| Finance expense, net | 57 | 583 | ||||||
| Total other income | 3,298 | 8,050 | ||||||
| Net loss | 19,388 | 22,597 | ||||||
| Other comprehensive loss: | ||||||||
| Foreign currency translation adjustment | (49 | ) | (24 | ) | ||||
| Comprehensive loss | $ | 19,339 | $ | 22,573 | ||||
| Basic and diluted loss per share | $ | 31.22 | $ | 4,106 | ||||
| Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share | 621,094 | 5,503 | ||||||